View Generic ICR - OIRA Conclusion



0910-0695 201712-0910-001
Historical Active 201711-0910-001
HHS/FDA CDER
Data to Support Drug Product Communications
Extension without change of a currently approved collection   No
Regular
Approved without change 02/14/2018
Retrieve Notice of Action (NOA) 12/28/2017
Prior terms remain in effect. This generic clearance for FDA/CDER is approved for 3 years under the following conditions: (1) For individual "tests," FDA shall submit a generic IC in ROCIS along with: (a) an abbreviated supporting statement in the template agreed to by OMB and FDA (including a statement of need, intended use of information, description of respondents, date(s) and location(s), collection procedures, justification for any proposed incentive, etc.); (b) participant screeners, and (c) instruments/moderator guides. (2) OMB will respond with clearance or questions within 10 working days.
  Inventory as of this Action Requested Previously Approved
02/28/2021 36 Months From Approved 02/28/2018
43,875 0 35,603
9,620 0 9,625
0 0 0